Hemostatic variables and ischemic cardiovascular disease: Do we need a concerted effort for more profitable future clinical investigations?

Cardiovascular Drugs and Therapy

Volumn 10, Issue 6, 1997, Pages 743-749

  Di Minno, Giovanni ^a   Mancini, Francesco Paolo ^b   Margaglione, Maurizio ^b  

^a Clinica Medica   (Italy)

^b NONE

Author keywords

Hemostatic predictors; Myocardial infarction; Stroke

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

ATHEROSCLEROSIS; BRAIN ISCHEMIA; HEALTH CARE POLICY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMOSTASIS; HUMAN; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; STROKE; THROMBOSIS; TREATMENT PLANNING;

ARTERIOSCLEROSIS; CEREBROVASCULAR DISORDERS; DISEASE PROGRESSION; HEMOSTASIS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PREDICTIVE VALUE OF TESTS; THROMBOSIS;

EID: 0030932326     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00053032     Document Type: Review

References (60)

1. Koss R. The pathogenesis of atherosclerosis. An update. N Engl J Med 1986;314:488-500.
2. Munro JM, Cotran RS. The pathogenesis of atherosclerosis: Atherogenesis and inflammation. Lab Invest 1988;58: 249-261.
3. Steinberg D. The cholesterol controversy is over. Why did it take so long? Circulation 1989;80:1070-1078.
4. De Witt SG. Cholesterol revisited. Molecule, medicine, and media. Arteriosclerosis 1989;9:430-438.
5. Fuster V, Badimon L, Badimon J, Chesebro J. The pathogenesis of coronary artery disease and the acute coronary syndromes N Engl J Med 1992;326:242-250.
6. Falk E. Unstable angina with fatal outcome: Dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 1985;71:699-708.
7. Davies MJ, Thomas CA. Plaque fissuring - the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985;53:363-373.
8. Saffitz JE, Schwartz CJ. Coronary atherosclerosis and thrombosis underlying acute myocardial infarction. Cardiol Clin 1987;5:21-30.
9. Schwartz CJ, Valente AJ, Kelley JL, Sprague EA, Edwards EH. Thrombosis and the development of atherosclerosis: Rokitansky revisited. Semin Thromb Hemost 1988; 14:189-195.
10. Bini A, Kudrik BJ. Fibrin and its derivatives in the normal and diseased vessel wall. In: Plasminogen Activation in Fibrinolysis, in Tissue Remodelling and in Development. Ann NY Acad Sci 1992;667:112-126.
11. Constantinides P. Cause of thrombosis in human atherosclerotic arteries. Am J Cardiol 1990;66:37G-40G.
12. Smith EL, Thompson WD. Fibrin as a cofactor in atherogenesis. Thromb Res 1994;73:1-19.
13. Hart RG, Kanter MC. Hematologic disorders and ischemic stroke. A selective review. Stroke 1990;21:1111-1121.
14. Hamsten A. Hemostatic function and coronary artery disease. N Engl J Med 1995;332:677-678.
15. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, Parts I, II and III. Br Med J 1994;308:81-106, 159-168, and 235-246.
16. Heller HF, Chinn S, Tunstall Pedoe HD, Rose G. How well can we predict coronary heart disease? Findings in the United Kingdom Heart Disease Prevention Project. Br Med J 1984;288:1409-1411.
17. Ernst E, Hammerschmidt DE, Bagge U, Matrai A, Dormandy JA. Leukocytes and the risk of ischemic disease. JAMA 1987;257:2318-2324.
18. Di Minno G, Mancini M. Measuring plasma fibrinogen to predict stroke and myocardial infarction. Arteriosclerosis 1990;10:1-7.
19. Ernst E, Resh KL. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review from the literature. Ann Intern Med 1993;118:956-963.
20. Margaglione M, Grandone E, Mancini FP, Di Minno G. Drugs affecting plasma fibrinogen levels. Implications for new antithrombotic strategies. Progr Drug Res 1995;46: 170-181.
21. Hamsten A, De Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987;2:3-9.
22. Auwerx J, Bouillon R, Collen D, Gebeors J. Tissue type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 1988;8:68-72.
23. Juhan-Vague I Alessi MC, Joly P, et al. Plasma plasminogen activator inhibitor 1 in angina pectoris. Influence of plasma insulin, and acute-phase response. Arteriosclerosis 1989;9:381-387.
24. Schaefer EJ, Lamon-Fava S, Jenner JL, et al. Lipoprotein(a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 1994;271:999-1003.
25. Ridker PM, Stampfer MJ, Hennekens CH. Plasma concentrations of lipoprotein(a) and the risk of future stroke. JAMA 1995;273:1269-1273.
26. Scanu AM, Fless GM. Lipoprotein (a). Heterogeneity and biological relevance. J Clin Invest 1990;85:1709-1715.
27. De Simone G, Devereux RB, Chien S, Alderman MH, Atlas SA, Laragh JH. Relation of blood viscosity to demographic and physiologic variables in apparently normal adults. Circulation 1990;81:107-117.
28. Lowe GDO, Drummond MM, Lorimer AR, Hutton I, Forbes CD, Prentice CRM, Barbenel JC. Relation between extent of coronary artery disease and blood viscosity. Br Med J 1980;2:673-674.
29. De Simone G, Devereux RB, Roman MJ, et al. Gender differences in left ventricular anatomy, blood viscosity and volume regulatory hormones in young adults. Am J Cardiol 1991;68:1704-1708.
30. Ernst EEW, Matrai A. Intermittent claudication, exercise and blood rheology. Circulation 1987;76:1110-1114.
31. Margaglione M, Grandone E, Mancini FP, Di Minno G. Genetic modulation of plasma fibrinogen concentrations: Possible importance of interleukin-6. J Thromb Thrombolysis 1996;3:51-56.
32. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-lin HepG2 cells. J Biol Chem 1993;268:10739-10745.
33. Valtonen VV. Infection as a risk factor for infarction and atherosclerosis. Ann Med 1991;23:539-543.
34. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington diabetes survey. Lancet 1988;2:530-533.
35. Mattock MB, Morrish NJ, Viberti GC, Keen H, Fitzgerald AP, Jackson G. Microalbuminuria as a predictor of mortality in NIDDM: A prospective study. Diabetes 1992;41: 736-741.
36. Messent J, Eliott T, Jarret RJ, Keen H, Viberti GC. The prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: A 23 years follow-up study. Kidney Int 1992;41:836-839.
37. Borch-Johnsen K, Kreiner S. Proteinuria: Value as predictor of cardiovascular mortality in insulin-dependent diabetes. Br Med J 1987;294:1651-1654.
38. Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, Deckert T. Coronary heart disease in young type I (insulin-dependent) diabetic patients with and without diabetic nephropathy: Incidence and risk factors. Diabetologia 1987; 30:144-148.
39. Morrish NJ, Stevens LK, Head J, Fuller JH, Jarrett RJ, Keen K. A prospective study of mortality among middle-aged diabetic patients: The London cohort of the WHO Multinational Study of Vascular Disease in diabetics). I: Causes and death rates. Diabetologia 1990;33:538-541 and 542-548.
40. Morrish NJ, Stevens LK, Head J, Fuller JH, Keen K, Jarrett RJ. Incidence of macrovascular disease in diabetes mellitus: The London cohort of the WHO Multinational Study of Vascular Disease in Diabetics). Diabetologia 1991;34: 584-589 and 590-594.
41. Jones SL, Close CF, Mattock MB, Jarrett RJ, Keen H, Viberti GC. Plasma lipid and coagulation factor concentration in insulin-dependent diabetics with microalbuminuria. Br Med J 1989;298:487-490.
42. Mattock MB, Fitzgerald A, Keen H, Viberti GC, Morrish NJ, Jackson PG. Hypercholesterolemia explains much of the predictive power of microalbuminuria for mortality in type 2 (non-insulin-dependent) diabetes. Diabetologia 1991; (Suppl 2):A11.
43. Casale PN, Devereux RB, Milner M, Zullo M, Harshfield GA, Pickering TG, Laragh JH. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986;105:173-178.
44. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Left ventricular mass and incidence of coronary heart disease in an elderly cohort. Ann Intern Med 1989;110: 101-107.
45. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-1566.
46. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345-352.
47. Cooper RS, Simmons BE, Castaner A, Santhanam V, Ghali J, Mar M. Left ventricular hypertrophy is associated with worse survival independent of left ventricular function and number of coronary arteries severely narrowed. Am J Cardiol 1990;65:441-445.
48. Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989;36:286-290.
49. Blake J, Devereux RB, Herrold EMcM, Borer JF, Laragh JH. Relation of concentric left ventricular hypertrophy and extracardiac target organ damage to supranormal left ventricular performance in established essential hypertension. Am J Cardiol 1988;62:246-252.
50. Fujita M, Mikuniya A, McKown DP, Franklin D. Regional myocardial volume alterations induced by brief repeated coronary occlusion in conscious dogs. J Am Coll Cardiol 1988;12:1048-1053.
51. Nguyen DN, Ghaddar H, Stinson V, Chambless LE, Wu KK. ARIC hemostatic study-IV. Intraindividual variability and reliability of hemostatic factors. Thromb Haemost 1995; 73:256-260.
52. Bauer KA. Detection of a prethrombotic state. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. Haemostasis and Thrombosis. New York: Churchill-Livingstone, 1994:1189-1198.
53. Martin JF, Bath PMW, Burr ML. Influence of platelet size on outcome after myocardial infarction. Lancet 1991;338: 1409-1411.
54. Patrono C, Davis G, Ciabattoni G. Thromboxane biosynthesis and metabolism in relation to cardiovascular risk factors. Trends Cardiovasc Med 1992;2:15-20.
55. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-1057.
56. Triplett DA. Antiphospholipid protein antibodies: Laboratory detection and clinical relevance. Thromb Res 1995;78: 1-31.
57. Thompson SG, Kienast J, Pyke SDM, Haverkate F, Van De Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635-641.
58. Consensus Conference. Prevention of venous thrombosis and pulmonary embolism. JAMA 1986;256:744-749.
59. Whincup PH, Cook DG, Phillips AN, Shaper AG. ABO blood groups and ischaemic heart disease in British men. Br Med J 1990;300:1679-1682.
60. Yarnell JWG, Baker IA, Sweetnam PM, Bainton D, O'Brien JR, Whitehead PJ, Elwood PC. Fibrinogen, viscosity and white blood cell count are major risk factors for ischemic heart disease. Circulation 1992;83:836-844.